cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cytokinetics Inc
18 own
13 watching
Current Price
$46.87
$1.64
(3.63%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
6,210.29M
52-Week High
52-Week High
86.63000
52-Week Low
52-Week Low
44.49000
Average Volume
Average Volume
2.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization6,210.29M
icon52-Week High86.63000
icon52-Week Low44.49000
iconAverage Volume2.3M
iconDividend Yield--
iconP/E Ratio--
What does the Cytokinetics Inc do?
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.
Read More
How much money does Cytokinetics Inc make?
News & Events about Cytokinetics Inc.
Zolmax
1 year ago
Cytokinetics, Incorporated (NASDAQ:CYTK Get Rating) CEO Robert I. Blum sold 12,500 shares of the businesss stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $37.06, for a total transaction of $463,250.00. Following the transaction, the chief ...
TipRanks Financial Blog
1 year ago
In a report released yesterday, Chris Shibutani from Goldman Sachs reiterated a Buy rating on Cytokinetics (CYTK Research Report), with a price t... In a report released yesterday, Chris Shibutani from Goldman Sachs reiterated a Buy rating on Cytokinetics (CYTK &#8211...
Zolmax
1 year ago
Cytokinetics, Incorporated (NASDAQ:CYTK Get Rating) CEO Robert I. Blum sold 12,500 shares of the stock in a transaction dated Friday, April 28th. The shares were sold at an average price of $37.68, for a total value of $471,000.00. Following the completion of the sale, the chief executive officer ...
TipRanks Financial Blog
1 year ago
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK Research Report) and Neurocri... Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK Research Report) and Neurocrine...
Globe Newswire
1 year ago
Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- ...
Frequently Asked Questions
Frequently Asked Questions
What is Cytokinetics Inc share price today?
plus_minus_icon
Can Indians buy Cytokinetics Inc shares?
plus_minus_icon
How can I buy Cytokinetics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cytokinetics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cytokinetics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cytokinetics Inc?
plus_minus_icon
What is today’s market capitalisation of Cytokinetics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cytokinetics Inc?
plus_minus_icon
What percentage is Cytokinetics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cytokinetics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$46.87
$1.64
(3.63%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$84.59
$-4.68 (-5.24 %)
Seres Therapeutics Inc
Seres Therapeutics Inc
$0.77
$-0.05 (-5.87 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$118.88
$0.45 (0.38 %)
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
$39.69
$1.44 (3.76 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$84.59
$-4.68 (-5.24 %)
Seres Therapeutics Inc
Seres Therapeutics Inc
$0.77
$-0.05 (-5.87 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$118.88
$0.45 (0.38 %)
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
$39.69
$1.44 (3.76 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00